ClinicalTrials.gg
AvailableNCT04689360Updated Oct 27, 2026

An Intermediate Size Expanded Access Protocol of Elamipretide

An expanded access record providing elamipretide in Mitochondrial Diseases and Barth Syndrome, sponsored by Stealth BioTherapeutics Inc.. Available. Open to participants aged 1 Year to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Stealth BioTherapeutics Inc. · Expanded access

How we know

Updated Oct 27, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Intermediate-size population
Ages
1 Year to 80 Years
Sex
All
01

Study summary

Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor to learn more about this program. The treating physician must contact StealthBiotherapeutics using the Expanded Access Program Contacts provided. Elamipretide will only be made available after careful review of an individual request submitted by the treating physician. The initiation and conduct of the treatment with elamipretide for an individual patient, and compliance with this treatment guideline, will be under the full and sole responsibility of the treating physician.

02

Conditions studied

  • Mitochondrial Diseases
  • Barth Syndrome

Keywords

  • Barth
03

In context

Mitochondrial Diseases

189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.

Browse Mitochondrial Diseases studies →

Lead sponsor

Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
1 Year to 80 Years
Sexes eligible
All

Eligibility criteria

Key Inclusion Criteria:

  1. ≥1 year and ≤ 80 years of age
  2. Patients with genetically confirmed rare primary mitochondrial diseases

    1. observed cardiomyopathy, renal impairment, neuropathic, or ophthalmic manifestation
    2. where such disease is serious or life-threatening and no comparable or satisfactory alternative therapy options available.
  3. Patients without genetic confirmation of a rare disease with known mitochondrial dysfunction but do exhibit serious or life-threatening clinical manifestations of mitochondrial dysfunction.
  4. Is self-able or has caregiver willing and able to administer SC injection.
  5. Would potentially benefit from treatment with elamipretide and cannot be treated satisfactorily with any approved medicinal product in the opinion of the treating physician.

Key Exclusion Criteria:

  1. Known to elamipretide or any .
  2. Women who are pregnant, are planning on becoming pregnant, or are breast-feeding.
  3. Patients receiving any other agent within 30 days of dosing.
  4. Any active, serious psychiatric, medical, or other conditions/situations which, in the treating physician's opinion, could compromise the patient's safety.
  5. Patients with Confirmed Barth Syndrome
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

  • Elamipretide is an aromatic-cationic tetrapeptide that readily penetrates cell membranes and transiently localizes to the inner mitochondrial membrane.

    Also known as: MTP-131

06

Where to request access

No study locations are listed for this record.

07

Updates

2 registry updates since Sep 25, 2026
Eligibility
Criteria revised in 2 updates
What changed on Oct 16, 2026
  • Edited≥1 year and ≤ 80 years of age or ≥12 years for Barth Syndrome in SPIES-007
What changed on Oct 27, 2026
  • EditedPatients with genetically confirmed rare primary mitochondrial diseases including Barth Syndrome
  • AddedPatients with Confirmed Barth Syndrome
across 2 updates, Oct 16, 2026 – Oct 27, 2026
Show all 2 updates
  1. Oct 27, 2026
    Eligibility 1 criterion edited, 1 added
    What changed in the criteria
    • EditedPatients with genetically confirmed rare primary mitochondrial diseases including Barth Syndrome
    • AddedPatients with Confirmed Barth Syndrome
  2. Oct 16, 2026
    Eligibility 1 criterion edited
    What changed in the criteria
    • Edited≥1 year and ≤ 80 years of age or ≥12 years for Barth Syndrome in SPIES-007
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

08

Registry details

Key details

Study ID
NCT04689360
Responsible party
Sponsor
First posted
Dec 30, 2020
Last update
Oct 27, 2026

Study contacts

Donna Cowan
Contact
donna.cowan@stealthbt.com
617.600.6888
Stealth EAP
Contact
EAP@stealthbt.com
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion